Covariates were all variables expected to be associated with mini‐consolidations versus IDAC (age, gender, performance status, WBC, 2017 ELN risk, secondary versus de novo AML, NPM1 and FLT3‐ITD mutations, study period, history of cytotoxic treatment, and targeted therapy added to induction and inclusion in a clinical trial). Here, NPM1 is linked to acute myeloid leukemia.